Company intelligence / Profile preview
Matricelf
Tel Aviv, Tel Aviv District, Israelmatricelf.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Matricelf has reported compelling preclinical results in FDA-accepted animal models of spinal cord injury, demonstrating significant functional recovery and safety. First-in-human clinical trial is planned for 2026, and a compassionate use request for a spinal cord injury patient has been submitted in collaboration with Sheba Medical Center.[1][2]
- Therapeutic areas
- CardiovascularNeurologyOphthalmology
- Modalities
- Induced pluripotent stem cell derived therapyCell therapyHydrogel-based drug delivery therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sheba Medical Center (clinical development, Israel)[2]
Beyond the preview
Go deeper on Matricelf.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matricelf.